title: Preferred treatment frequency in patients receiving androgen deprivation therapy for advanced prostate cancer.
abstract: OBJECTIVE
  The aim of this study was to assess patient preference regarding the length of treatment intervals of androgen deprivation therapy (ADT) with gonadotropin-releasing hormone agonists for prostate cancer.
  
  
  METHODS
  The study was conducted as a questionnaire-based, cross-sectional study at a large university hospital. A specific questionnaire was developed based on current literature, clinical experience and a pilot phase of the study. The primary endpoint was preferred treatment frequency. Secondary outcome measures included reasons for preferred treatment frequency, treatment satisfaction and side-effects. Overall, 238 men receiving ADT for prostate cancer were presented with the questionnaire between September 2011 and May 2012. Descriptive statistics, the chi-squared test and multiple regression were used for analyses.
  
  
  RESULTS
  In total, 176 questionnaires (74%) were available for analysis. A total of 38.1% of participants preferred frequent treatment ("Every month", "Every third month"), 32.4% preferred infrequent treatment ("Every sixth month", "Every twelfth month") and 29.6% stated that length of the treatment intervals made no difference (p = 0.37). Patients with disease progression were most likely to prefer frequent treatment (odds ratio 4.4, 95% confidence interval 1.9-10.4). Overall, 84.1% were satisfied with treatment while one patient (0.6%) was dissatisfied. Nine per cent indicated severe side-effects.
  
  
  CONCLUSIONS
  Less frequent ADT treatment may help to lower the pressure on healthcare systems and may be of benefit for a large group of patients. However, it cannot be prescribed blindly without possibly affecting patient satisfaction. The choice of treatment intervals should be made in collaboration between the physician and the patient.
authors.affiliation: Department of Urology, Herlev Hospital , Herlev , Denmark.
authors.forename: Mikkel
authors.initials: M
authors.lastname: Fode
authors.forename: Torben K
authors.initials: TK
authors.lastname: Nielsen
authors.forename: Muhammad
authors.initials: M
authors.lastname: Al-Hamadani
authors.forename: Jesper R
authors.initials: JR
authors.lastname: Andersen
authors.forename: Henrik
authors.initials: H
authors.lastname: Jakobsen
authors.forename: Jens
authors.initials: J
authors.lastname: Sønksen
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use*; D003430:Cross-Sectional Studies; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D057240:Patient Preference; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013997:Time Factors
chemical_list: D000726:Androgen Antagonists; D007987:Gonadotropin-Releasing Hormone